Skip to content
    SymBiosis logo

    SymBiosis

    Bentonville, Arkansas, United StatesFounded 2019
    symbiosis.vcLinkedIn
    Biotech & Life SciencesHealthcare

    SymBiosis Capital Management is a venture capital firm based in Bentonville, Arkansas, investing in biotherapeutics and biotechnology companies developing solutions for serious and life-threatening diseases. The firm targets companies at the intersection of biology and engineering, typically deploying $5-15 million per investment with the ability to scale to over $30 million.

    78% of their portfolio is in Biotech & Life Sciences. Deal activity increased 33% year-over-year (4 deals in the last 12 months). Their most common stage is series-b (41% of deals). Average disclosed round size is $126.0M (across 29 rounds with reported amounts).

    Find people at SymBiosis on Goldilocks AI

    Portfolio

    22

    Fund Size

    $357.2M

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    CU

    Chidozie Ugwumba

    Founder & Managing Partner

    AC

    Aleksei Cremo

    Principal, Investments

    BD

    Brendon Dobbs

    Vice President, AI & Analytics

    CK

    Caleb Kreutner

    Senior Vice President, Finance & Operations

    CS

    Catherine Shoults, PhD

    Senior Vice President, AI & Analytics

    GS

    Geraldine Schott, PhD

    Vice President, Investments

    AI

    Allie Ivy, PhD

    Associate, Investments

    AV

    Aryan Vora

    Associate, Investments

    TG

    Trevor Goethe

    Associate, Finance & Operations

    SH

    Sarah Hernandez

    Senior Executive Assistant

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    37 investments
    CompanyRoundAmountDate
    CCorxelSeries D$287MSep 2026
    Solve Therapeutics logoSolve TherapeuticsBridge$120MSep 2026
    Fore Biotherapeutics logoFore BiotherapeuticsUnknown$67.4MJul 2026
    R1 Therapeutics logoR1 TherapeuticsSeries A$77.5MMar 2026
    CCorxelSeries D$287MJan 2026
    CCorxel Pharmaceuticals LimitedSeries D$287MJan 2026
    Solve Therapeutics logoSolve TherapeuticsUnknown$120MJan 2026
    Metsera logoMetseraSeries B$215MJan 2026
    R1 Therapeutics logoR1 TherapeuticsSeries A$77.5MJan 2026
    SanegeneBio logoSanegeneBioSeries B$110MJan 2026
    Fore Biotherapeutics logoFore BiotherapeuticsSeries D$38MMay 2025
    AdvanCell logoAdvanCellSeries C$112MJan 2025
    SanegeneBio logoSanegeneBioSeries B$110MJan 2025
    Metsera logoMetseraSeries B—Nov 2024
    Evommune logoEvommuneSeries C$115MOct 2024
    Aardvark logoAardvarkSeries C$85MMay 2024
    Ensoma logoEnsomaSeries B$135MMay 2023
    Evommune logoEvommuneSeries B$50MApr 2023
    Solve Therapeutics logoSolve TherapeuticsSeries A$126MDec 2022
    SSalioGen TherapeuticsSeries B$115MJan 2022
    SalioGen logoSalioGenSeries B$115MJan 2022
    Maat Pharma logoMaat PharmaSeries B—Dec 2020
    Maat Pharma logoMaat PharmaSeries B—Dec 2020
    Siolta Therapeutics logoSiolta TherapeuticsSeries B$30MSep 2020
    Clene Nanomedicine logoClene NanomedicineSeries D$42.5MAug 2020
    Page 1 of 2

    Top Co-Investors

    RA Capital Management7 shared
    Abingworth LLP7 shared
    HBM Healthcare Investments7 shared
    Seventure Partners7 shared
    SR One6 shared
    F-Prime Capital5 shared
    Cormorant Asset Management5 shared
    Alexandria Venture Investments5 shared
    Wellington Management5 shared
    The Invus Group, LLC5 shared
    Biocodex5 shared
    Fidelity Investments4 shared
    ARCH Venture Partners4 shared
    Eli Lilly and Company4 shared
    T. Rowe Price4 shared
    TCG Crossover4 shared
    Bpifrance4 shared
    Adage Capital Management3 shared
    B Capital3 shared
    Catalio Capital Management3 shared

    Last updated: 7 October 2026